Janneke P. C. Grutters
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Janneke P. C. Grutters has a total of 425 co-authors. Here are the top co-authors by number of shared publications:
- Manuela A. Joore
Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), Maastricht, The Netherlands
22 shared publications - Maroeska M. Rovers
Department of Medical Imaging, Radboudumc, Nijmegen, The Netherlands
16 shared publications - Gert Jan van der Wilt
IQ Health, Radboud University Medical Center, Nijmegen, the Netherlands
15 shared publications - Bram L. T. Ramaekers
Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+, Maastricht, The Netherlands
10 shared publications Dirk De Ruysscher
10 shared publications- Philippe Lambin
The D-Lab, Department of Precision Medicine, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, Netherlands
9 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (6) , 1658-1666
Mapping the mRS Into the EQ-5D-5L in Patients With Ischemic Stroke
BACKGROUND: Mapping concerns the cross-walking of one health-related quality of life instrument to another. This study aimed to translate the modified Rankin Scale (mRS) score at 3 months after ischemic stroke into 5-level version of the EQ-5D (EQ-5D-5L)–based utility values, which may be used for the derivation of quality-adjusted life years for cost-effectiveness analyses. METHODS: Data from 3 Dutch multicenter phase III clinical trials in ischemic stroke were pooled (MR CLEAN [Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands]-NO-IV, MR CLEAN-MED, and MR CLEAN-LATE). The mRS and EQ-5D-5L were assessed by telephone interview at 3 months poststroke. The correlation (Spearman coefficient) between the mRS and each EQ-5D-5L domain was assessed. Various direct and indirect mapping algorithms were explored. Model performance (predictive ability) was assessed using bootstrapping in the full testing set (mRS score 0–5) and in patients with independent (0–2) and dependent (3–5) mRS scores separately. Results were validated in an external validation set derived from a cross-sectional Dutch study. Final utility estimates per mRS score were assessed in the pooled trial and external validation data set. RESULTS: The EQ-5D-5L dimensions self-care, daily activities, and mobility demonstrated the strongest correlation to the mRS ( ρ =0.46–0.70). Correlation coefficients of the pain and anxiety dimensions were relatively poor ( ρ =0.37–0.45). Indirect mapping with a multinomial logit model was identified as the preferred mapping algorithm. In the pooled data set, the median (interquartile range) age was 71 (62–79), and 56% of patients were male. Mean (SD) fitted utility values per mRS score were; mRS score 0: 0.947 (0.004); mRS score 1: 0.860 (0.009); mRS score 2: 0.758 (0.013); mRS score 3: 0.597 (0.017); mRS score 4: 0.352 (0.017); and mRS score 5: 0.147 (0.017). CONCLUSIONS: The mean utility weights provided in this study may be used for the direct estimation of quality-adjusted life years from mRS scores. Furthermore, the multinomial logit model may be used to derive utility values from new data sets with different country-specific utility tariffs. Our results are ideally suited for application in cost-effectiveness analyses.
- 1 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (6) , 1658-1666
Open AccessMapping the mRS Into the EQ-5D-5L in Patients With Ischemic Stroke
BACKGROUND: Mapping concerns the cross-walking of one health-related quality of life instrument to another. This study aimed to translate the modified Rankin Scale (mRS) score at 3 months after ischemic stroke into 5-level version of the EQ-5D (EQ-5D-5L)–based utility values, which may be used for the derivation of quality-adjusted life years for cost-effectiveness analyses. METHODS: Data from 3 Dutch multicenter phase III clinical trials in ischemic stroke were pooled (MR CLEAN [Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands]-NO-IV, MR CLEAN-MED, and MR CLEAN-LATE). The mRS and EQ-5D-5L were assessed by telephone interview at 3 months poststroke. The correlation (Spearman coefficient) between the mRS and each EQ-5D-5L domain was assessed. Various direct and indirect mapping algorithms were explored. Model performance (predictive ability) was assessed using bootstrapping in the full testing set (mRS score 0–5) and in patients with independent (0–2) and dependent (3–5) mRS scores separately. Results were validated in an external validation set derived from a cross-sectional Dutch study. Final utility estimates per mRS score were assessed in the pooled trial and external validation data set. RESULTS: The EQ-5D-5L dimensions self-care, daily activities, and mobility demonstrated the strongest correlation to the mRS ( ρ =0.46–0.70). Correlation coefficients of the pain and anxiety dimensions were relatively poor ( ρ =0.37–0.45). Indirect mapping with a multinomial logit model was identified as the preferred mapping algorithm. In the pooled data set, the median (interquartile range) age was 71 (62–79), and 56% of patients were male. Mean (SD) fitted utility values per mRS score were; mRS score 0: 0.947 (0.004); mRS score 1: 0.860 (0.009); mRS score 2: 0.758 (0.013); mRS score 3: 0.597 (0.017); mRS score 4: 0.352 (0.017); and mRS score 5: 0.147 (0.017). CONCLUSIONS: The mean utility weights provided in this study may be used for the direct estimation of quality-adjusted life years from mRS scores. Furthermore, the multinomial logit model may be used to derive utility values from new data sets with different country-specific utility tariffs. Our results are ideally suited for application in cost-effectiveness analyses.
- Open Access
- 3 April 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (7) , 102822
Chimeric antigen receptor–natural killer cell therapy in first-relapse epithelial ovarian cancer: an early health-economic evaluation in the Netherlands
- 3 April 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (7) , 102822
Open AccessChimeric antigen receptor–natural killer cell therapy in first-relapse epithelial ovarian cancer: an early health-economic evaluation in the Netherlands
- Open Access
- 6 November 2025
- Published by Elsevier in Health Policy
- Vol. 163, 105486
How do strategy, scanning, and assessment shape decision-making on technologies in hospitals? insights from a qualitative study in Dutch hospitals
- 6 November 2025
- Published by Elsevier in Health Policy
- Vol. 163, 105486
Open AccessHow do strategy, scanning, and assessment shape decision-making on technologies in hospitals? insights from a qualitative study in Dutch hospitals
- Top Cited PapersOpen Access
- 2 June 2025
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 41 (1) , 1-27
Defining early health technology assessment: building consensus using Delphi technique
Although early health technology assessment (HTA) is increasingly being used to guide and inform decisions on product development, a consensus definition is currently lacking. A working group under the HTA International Society was established to develop a consensus-based definition of early HTA. The working group developed a definition using an iterative process that comprised five stages of work and included a two-round Delphi survey with 133 respondents in the first and 99 respondents in the second round of the survey, with various backgrounds and levels of expertise. Following this process, the working group reached the first consensus-based definition of early HTA, which is an HTA conducted to inform decisions about subsequent development, research, and/or investment by explicitly evaluating the potential value of a conceptual or actual health technology. In total, 86 (87 percent) of the 99 panelists who participated in the second round of the Delphi survey either strongly agreed or agreed with this definition. This consensus definition represents an important milestone in early HTA. It will enhance the uniformity of terminology, increasing the visibility of research and policy in this field. We also hope that it will act as a catalyst sparkling further research and developments in this discipline.
- 2 June 2025
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 41 (1) , 1-27
Top Cited PapersOpen AccessDefining early health technology assessment: building consensus using Delphi technique
Although early health technology assessment (HTA) is increasingly being used to guide and inform decisions on product development, a consensus definition is currently lacking. A working group under the HTA International Society was established to develop a consensus-based definition of early HTA. The working group developed a definition using an iterative process that comprised five stages of work and included a two-round Delphi survey with 133 respondents in the first and 99 respondents in the second round of the survey, with various backgrounds and levels of expertise. Following this process, the working group reached the first consensus-based definition of early HTA, which is an HTA conducted to inform decisions about subsequent development, research, and/or investment by explicitly evaluating the potential value of a conceptual or actual health technology. In total, 86 (87 percent) of the 99 panelists who participated in the second round of the Delphi survey either strongly agreed or agreed with this definition. This consensus definition represents an important milestone in early HTA. It will enhance the uniformity of terminology, increasing the visibility of research and policy in this field. We also hope that it will act as a catalyst sparkling further research and developments in this discipline.
- Open Access
- 14 May 2025
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 34, 100314
Exploratory health economic analyses to support decisions within the innovation process in radiotherapy: Magnetic Resonance Linear Accelerator as a case study
- 14 May 2025
- Published by Elsevier in Technical Innovations & Patient Support in Radiation Oncology
- Vol. 34, 100314
Open AccessExploratory health economic analyses to support decisions within the innovation process in radiotherapy: Magnetic Resonance Linear Accelerator as a case study
- Open Access
- 28 October 2024
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-13
Preferences for genetic interventions for SCA and Huntington’s disease: results of a discrete choice experiment among patients
Background: Although genetic interventions are on the horizon for some polyglutamine expansion diseases, such as subtypes of spinocerebellar ataxia (SCA) and Huntington’s disease (HD), the patients’ preferences regarding these new therapies are unclear. This study aims to get insight into what extent different characteristics of genetic interventions affect the preferences of patients with SCA and HD with regard to these interventions. Methods: Manifest and premanifest patients with SCA or HD were recruited online by platforms of patient associations. The respondents conducted a questionnaire that included a discrete choice experiment (DCE). The experimental design included 24 choice sets, but these were divided into three blocks of eight to reduce the number of tasks per respondent. Each choice set included two alternative treatments and consisted of four attributes (mode and frequency of administration, chance of a beneficial effect, risks, and follow-up), each with three or four different levels. The forced choice-elicitation format was used. Data were analyzed by using a multinominal logistic regression model. Results: Responses of 216 participants were collected. The mode and frequency of administration of a genetic intervention, as well as the chance of a beneficial effect both influence the choice for a genetic intervention. Respondents less prefer repeated lumbar punctures compared to a single operation. As expected, a higher beneficial effect of treatment was preferred. Risks and follow-up did not influence the choice for a genetic intervention. Conclusions: The results can be used for the design and implementation of future genetic interventional trials as well as of patient-centered care pathways for rare movement disorders such as SCA and HD.
- 28 October 2024
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-13
Open AccessPreferences for genetic interventions for SCA and Huntington’s disease: results of a discrete choice experiment among patients
Background: Although genetic interventions are on the horizon for some polyglutamine expansion diseases, such as subtypes of spinocerebellar ataxia (SCA) and Huntington’s disease (HD), the patients’ preferences regarding these new therapies are unclear. This study aims to get insight into what extent different characteristics of genetic interventions affect the preferences of patients with SCA and HD with regard to these interventions. Methods: Manifest and premanifest patients with SCA or HD were recruited online by platforms of patient associations. The respondents conducted a questionnaire that included a discrete choice experiment (DCE). The experimental design included 24 choice sets, but these were divided into three blocks of eight to reduce the number of tasks per respondent. Each choice set included two alternative treatments and consisted of four attributes (mode and frequency of administration, chance of a beneficial effect, risks, and follow-up), each with three or four different levels. The forced choice-elicitation format was used. Data were analyzed by using a multinominal logistic regression model. Results: Responses of 216 participants were collected. The mode and frequency of administration of a genetic intervention, as well as the chance of a beneficial effect both influence the choice for a genetic intervention. Respondents less prefer repeated lumbar punctures compared to a single operation. As expected, a higher beneficial effect of treatment was preferred. Risks and follow-up did not influence the choice for a genetic intervention. Conclusions: The results can be used for the design and implementation of future genetic interventional trials as well as of patient-centered care pathways for rare movement disorders such as SCA and HD.
- 14 December 2023
- Published by SAGE Publications in Medical Decision Making
- Vol. 44 (2) , 127-128
Reporting Economic Evaluations with Value of Information Analyses Using the CHEERS Value of Information (CHEERS-VOI) Reporting Guideline
- 14 December 2023
- Published by SAGE Publications in Medical Decision Making
- Vol. 44 (2) , 127-128
Reporting Economic Evaluations with Value of Information Analyses Using the CHEERS Value of Information (CHEERS-VOI) Reporting Guideline
- Open Access
- 12 October 2023
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 39 (1) , 1-6
Response to “UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS: GUIDANCE OF THE HTAi-DIA WORKING GROUP”
Decision-Making on Drugs: Guidance of the HTAi-DIA Working Group" by Hogervorst et al. (1). We wish to commend HTAi, DIA, and the Working Group for selecting this important topic. To our surprise, the guidance only references a small subset of the extensive work on the topic of uncertainty in and outside of health technology assessment (HTA). Not referenced were articles on considerations around uncertainty in health (2-7), classifications of uncertainty in HTA (8-11) and outside HTA (12-16), and methods for uncertainty assessment (17-22), among others. For a scientific article in a scientific journal, methods and results of the scoping review are not described in sufficient detail. It remains unclear if and how the state of the art on uncertainty in HTA was used to develop the guidance. Specifically, the part on "building blocks comprising decision-making uncertainty" bears non-negligible similarity to published work that is identified in the authors' scoping review but not citedthe TRUST tool 2020 (11). TRUST considers the same uncertainty factors as outlined in the present article, including origin (location in TRUST), type (source in TRUST), impact/risk (same in TRUST), and relevance/judgment (appraisal in TRUST). The types of actionable uncertainty considered are also very similar: inaccurate (separated into imprecision, bias, and indirectness in TRUST); unavailable (same in TRUST); and non-understandable (transparency in TRUST). In line with existing classifications of uncertainty (8;16), TRUST also considers uncertainty stemming from methodological issues. TRUST does not include uncertainty from conflicting information, as this was considered to be reflected through imprecision or bias (4). TRUST is readily available, validated, practical, and used in practice (e.g., in Dutch Healthcare Institute reports). It is unclear how the presented guidance improves upon this. There is an opportunity to build upon the challenges other researchers in the area of uncertainty assessment in and outside of HTA have identified and the methods proposed to address these. The progress made on the following topics has not been sufficiently covered in the guidance, including but not limited to:
- 12 October 2023
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 39 (1) , 1-6
Open AccessResponse to “UNCERTAINTY MANAGEMENT IN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT DECISION-MAKING ON DRUGS: GUIDANCE OF THE HTAi-DIA WORKING GROUP”
Decision-Making on Drugs: Guidance of the HTAi-DIA Working Group" by Hogervorst et al. (1). We wish to commend HTAi, DIA, and the Working Group for selecting this important topic. To our surprise, the guidance only references a small subset of the extensive work on the topic of uncertainty in and outside of health technology assessment (HTA). Not referenced were articles on considerations around uncertainty in health (2-7), classifications of uncertainty in HTA (8-11) and outside HTA (12-16), and methods for uncertainty assessment (17-22), among others. For a scientific article in a scientific journal, methods and results of the scoping review are not described in sufficient detail. It remains unclear if and how the state of the art on uncertainty in HTA was used to develop the guidance. Specifically, the part on "building blocks comprising decision-making uncertainty" bears non-negligible similarity to published work that is identified in the authors' scoping review but not citedthe TRUST tool 2020 (11). TRUST considers the same uncertainty factors as outlined in the present article, including origin (location in TRUST), type (source in TRUST), impact/risk (same in TRUST), and relevance/judgment (appraisal in TRUST). The types of actionable uncertainty considered are also very similar: inaccurate (separated into imprecision, bias, and indirectness in TRUST); unavailable (same in TRUST); and non-understandable (transparency in TRUST). In line with existing classifications of uncertainty (8;16), TRUST also considers uncertainty stemming from methodological issues. TRUST does not include uncertainty from conflicting information, as this was considered to be reflected through imprecision or bias (4). TRUST is readily available, validated, practical, and used in practice (e.g., in Dutch Healthcare Institute reports). It is unclear how the presented guidance improves upon this. There is an opportunity to build upon the challenges other researchers in the area of uncertainty assessment in and outside of HTA have identified and the methods proposed to address these. The progress made on the following topics has not been sufficiently covered in the guidance, including but not limited to:
- Open Access
- 31 July 2023
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 39 (1) , e46
A first exploration of the economic consequences of an autonomous surgical robot for lateral skull base surgery: an early health technology assessment
Objectives: Lateral skull base procedures, such as translabyrinthine approach (TLA), are challenging. An autonomous surgical robot might be a solution to these challenges. Our aim is to explore in an early phase the economic consequences of an autonomous surgical robot compared with conventional TLA. Methods: An early decision analytic model was constructed in order to perform a step-wise threshold analyses and a sensitivity analysis to analyze the impact of the several factors on the incremental costs. Results: Using surgical robot results in incremental costs – EUR 5,562 per procedure – compared to conventional TLA. These costs are most reduced by higher number of procedures, followed by lower price of the robot, saved operation time, and reduced risk of complication, respectively. Conclusions: The incremental costs of using an autonomous surgical robot can be decreased by choosing applications with a high turnover rate, a long operation time, and a high complication rate.
- 31 July 2023
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 39 (1) , e46
Open AccessA first exploration of the economic consequences of an autonomous surgical robot for lateral skull base surgery: an early health technology assessment
Objectives: Lateral skull base procedures, such as translabyrinthine approach (TLA), are challenging. An autonomous surgical robot might be a solution to these challenges. Our aim is to explore in an early phase the economic consequences of an autonomous surgical robot compared with conventional TLA. Methods: An early decision analytic model was constructed in order to perform a step-wise threshold analyses and a sensitivity analysis to analyze the impact of the several factors on the incremental costs. Results: Using surgical robot results in incremental costs – EUR 5,562 per procedure – compared to conventional TLA. These costs are most reduced by higher number of procedures, followed by lower price of the robot, saved operation time, and reduced risk of complication, respectively. Conclusions: The incremental costs of using an autonomous surgical robot can be decreased by choosing applications with a high turnover rate, a long operation time, and a high complication rate.
- Open Access
- 8 May 2023
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (8) , 3799
Correction to: The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study
- 8 May 2023
- Published by Springer Nature in Journal of Neurology
- Vol. 270 (8) , 3799
Open AccessCorrection to: The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study